← Oncology Approval Tracker

FDA DECISION ·

Ziihera + Tevimbra

zanidatamab-hrii with tislelizumab-jsgr and chemotherapy · Jazz Pharmaceuticals / BeOne Medicines

FDA approvalNew or expanded indicationGastroesophageal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line fluoropyrimidine and platinum chemotherapy with zanidatamab and tislelizumab for adults with unresectable locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma and HER2 IHC 3+ or IHC 2+/ISH+ by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

This regimen combines a HER2-directed bispecific and checkpoint inhibition. HERIZON-GEA-01 showed improvements in both overall survival and progression-free survival against trastuzumab plus chemotherapy in the specified HER2-positive population.

What research teams should watch

Capture IHC and any reflex ISH result separately. Pharmacy, infusion and safety teams need to coordinate a multicomponent regimen and keep its HER2 criteria distinct from the Ziihera regimen without tislelizumab.

PRIMARY RECORDS

Sources